Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients.

• Status: Recruiting
• Trial end date: 2021-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

This prospective, non-randomised, open-label, clinical trial is conducting on polycystic ovary syndrome (PCOS) subjects to compare the effects of two pituitary suppression regimens; GnRH Agonist-Long Protocol and GnRH Antagonist-Flexible Protocol on clinical and embryological IVF/ICSI outcomes, and on the follicular fluid levels of Placental Growth Factor (PlGF); which is known for his pivotal role in the regulation of ovulation, embryo development, and implantation

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Damascus University
• Treatments: Cetrorelix; Chorionic Gonadotropin; Menotropins; Triptorelin Pamoate

Criteria

Inclusion Criteria:

• PCOS women diagnosed according to the Rotterdam criteria undergoing IVF/ICSI.

• Age: 18-39 years.

• Both ovaries present.

Exclusion Criteria:

• Age ≥ 40 years.

• History of three or more previous IVF failures.

• Patients with hormonal disorders like hyperprolactinemia, thyroid disorders.

• Patients who previously undergo Unilateral Oophorectomy.

• Patients with chronic diseases: diabetes mellitus, cardiovascular diseases, liver diseases, kidney diseases.

• Patients with diseases may affect IVF outcomes: Endometriosis, uterine fibroids, Hydrosalpinx, Adenomyosis, autoimmune diseases,

• Cancer.